Amgen Stock News

A drug from Amgen could give patients with a notoriously aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca.  Full results from a late-stage trial show that adding Amgen's Imdelltra to AstraZeneca's Imfinzi drug slashed the risk of death by 58% in patients with extensive-stage small cell lung cancer.

Nearly 80% of Patients Were Alive at One Year Versus 53% with IMFINZI Alone and Progression-Free Survival More Than Tripled Late-Breaking Phase 3 DeLLphi-305 Results  Presented in ESMO Presidential Symposium and Simultaneously Published in The New England Journal of Medicine Longer DeLLphi-303 Follow-Up Data Showed Median Overall Survival Exceeded 37 Months in First-Line Maintenance with IMDELL...

Amgen integrates sustainability goals in every part of its business with a holistic and innovative approach to manufacturing.

Amgen and AstraZeneca said on Tuesday their asthma drug helped reduce swallowing difficulties and achieved disease remission in 69% ​of patients with a type of chronic inflammatory disorder ‌of the esophagus.

Symptom Improvements Versus Placebo at Week 24 Were Sustained Through Week 52 Statistically Significant Total Endoscopic Remission with No Visible Inflammation or Fibrosis Attained Versus Placebo at Week 52 THOUSAND OAKS, Calif., Oct. 20, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the positive Phase 3 CROSSING trial that showed TEZSPIRE® (tezepelu...

A week that tested the financial markets showed the resilience of Dow Jones stocks. Apple and Coca-Cola were among nine standouts.

Some beaten-down consumer names are getting a boost as investors pull back from tech stocks.

Shares of AbbVie, Eli Lilly and Gilead Sciences are trading at or near record highs.